Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.55 |
| ▸ | PPARA | Q07869 | 8/20 | 0.55 |
| ▸ | PPARD | Q03181 | 7/20 | 0.55 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | PTGES | O14684 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12096661 | 0.90 | PPARG (0.68) | PPARGPPARAPPARDSRD5A2RORC | |
| SCHEMBL12096776 | 0.90 | PPARG (0.68) | PPARGPPARAPPARDRORC | |
| SCHEMBL12096921 | 0.89 | PPARG (0.48) | PPARGPPARAPPARDRORC | |
| SCHEMBL12096872 | 0.89 | PPARG (0.55) | PPARGPPARAPPARDSRD5A2PTGES | |
| SCHEMBL12096683 | 0.88 | PPARG (0.55) | PPARGPPARAPPARDSRD5A2RORC | |
| SCHEMBL12096684 | 0.88 | PPARG (0.55) | PPARGPPARAPPARDSRD5A2MEN1 | |
| SCHEMBL12096911 | 0.87 | PPARG (0.67) | PPARGPPARAPPARDSRD5A2RORC | |
| SCHEMBL12096798 | 0.87 | PPARG (0.54) | PPARGPPARAPPARDSRD5A2RORC | |
| SCHEMBL12096633 | 0.87 | PPARG (0.55) | PPARGPPARAPPARDSRD5A2RORC | |
| SCHEMBL12096709 | 0.86 | PPARG (0.54) | PPARGPPARAPPARDSRD5A2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232070-A1 | Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease | LABORATOIRES FOURNIER SA (FR) | 2012-09-13 | — | — | US | disclosed |
| CN-102596906-A | Use of indole derivatives as NURR-1 activators as agents for the treatment of Parkinson's disease | FOURNIER LAB SA | 2012-07-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232070-A1 | Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease | NCOR1, NR0B1, MTNR1A | PPARG 423/4885PPARA 564/4885PPARD 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.